Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for AbbVie Inc. (NYSE: ABBV), a pharmaceutical preparation manufacturing company focused on immunology, oncology, neuroscience, eye care and its Allergan Aesthetics portfolio. AbbVie’s filings provide structured insight into its financial condition, capital structure, research spending and key corporate events.
Recent Form 8‑K filings discuss items under “Results of Operations and Financial Condition,” including guidance for specific quarters and full‑year periods and the impact of acquired in‑process research and development (IPR&D) and milestones expense on diluted earnings per share. Other 8‑K disclosures describe settlements of litigation related to generic manufacturers of upadacitinib tablets (marketed as RINVOQ) and note that AbbVie’s common stock and multiple series of senior notes are registered and listed on the New York Stock Exchange.
Through this filings feed, users can access AbbVie’s current reports alongside its periodic reports when available, such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q. These documents typically contain details on research and development activities, manufacturing investments, and the performance of key therapeutic areas, as well as discussions of risk factors and capital allocation. For a company active in oncology and other complex therapeutic fields, these filings help explain how collaborations, licensing agreements and acquisitions are reflected in financial statements, particularly through acquired IPR&D and milestones expense.
Stock Titan enhances these filings with AI-powered summaries that highlight important sections, such as earnings guidance updates, litigation disclosures and changes in capital structure. Users can quickly see how items like AbbVie’s guidance revisions, settlement agreements or investment commitments appear in official SEC documents. Real-time updates from EDGAR, combined with AI explanations of forms such as 8‑K and, where applicable, 10‑K, 10‑Q and Form 4 insider transaction reports, allow investors and researchers to review ABBV’s regulatory record more efficiently and understand the context behind headline numbers and corporate announcements.
AbbVie Inc. reported Q3 2025 results. Net revenues were $15,776 million, up from $14,460 million a year ago, while operating earnings fell to $1,904 million from $3,831 million as the company recorded significant charges. Net earnings were $186 million and diluted EPS was $0.10.
Results reflect acquired IPR&D and milestones expense of $2,680 million in the quarter and intangible asset impairments of $847 million in cost of products sold tied to Resonic and Durysta. Interest expense, net, was $667 million. For the nine months ended September 30, 2025, net revenues were $44,542 million and net earnings were $2,410 million; operating cash flow was $13,812 million.
AbbVie completed or announced portfolio moves: Capstan Therapeutics (cash consideration of $2.1 billion; $1.9 billion recognized in IPR&D), Ichnos Glenmark ISB-2001 license (upfront $700 million), ADARx options (upfront $335 million), Gubra license (upfront $350 million), Nimble Therapeutics acquisition (aggregate $288 million). Subsequent to quarter end, AbbVie acquired Gilgamesh Pharmaceuticals for approximately $900 million upfront. Total equity was a deficit of $2,599 million as of September 30, 2025.
AbbVie Inc. (ABBV) filed an 8-K announcing Q3 2025 results. The company issued a press release for the third quarter ended September 30, 2025, and furnished it with this report.
The press release is included as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition). No financial figures are detailed in this report itself.
AbbVie Inc. filed a Form 8-K to update investors on how acquired in-process research and development (IPR&D) and milestone expenses will affect its 2025 earnings. For the third quarter of 2025, AbbVie expects to record $2.7 billion of acquired IPR&D and milestones expense on a pre-tax basis, which it says will have an unfavorable impact of $1.50 on both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. The company notes that results for the quarter ended September 30, 2025 are still preliminary and may change.
AbbVie reiterates that it does not forecast acquired IPR&D and milestones expense because the timing and occurrence of such transactions are uncertain, and prior 2025 guidance excluded these expenses beyond the second quarter. Including the third quarter 2025 acquired IPR&D and milestones expense, AbbVie now provides a full-year 2025 adjusted diluted earnings per share guidance range of $10.38 to $10.58, and a third quarter 2025 adjusted diluted earnings per share guidance range of $1.74 to $1.78.
Susan E. Quaggin, an AbbVie Inc. (ABBV) director, had 67 stock equivalent units credited to her account on 09/30/2025 at a unit value of $231.54. The filing shows these units are held in a grantor trust and are paid in cash generally at age 65 or upon retirement from the board; they earn returns as if invested in AbbVie stock. The report indicates a post-transaction beneficial ownership balance of 634 shares (including units acquired through a dividend reinvestment feature).
Robert J. Alpern, an AbbVie director, reported a Form 4 disclosing a non‑derivative acquisition on 09/30/2025 of 33 stock equivalent units credited at a per‑unit value of $231.54. The filing states these units are director fees credited to grantor trust accounts established by Abbott Laboratories and AbbVie and that AbbVie account units are payable in cash generally at age 65 or upon retirement from AbbVie’s board. The report shows a total beneficial ownership balance of 10,151 stock equivalent units (including amounts from dividend reinvestment). The Form 4 was signed by an attorney‑in‑fact on 10/02/2025.
AbbVie Inc. reported that it has settled litigation with all generic drug manufacturers that filed abbreviated new drug applications in the United States for generic versions of its upadacitinib tablets, marketed as RINVOQ. Based on these settlement and license agreements, and assuming pediatric exclusivity is granted, AbbVie does not expect any generic upadacitinib tablet products to enter the U.S. market before April 2037, subject to standard acceleration provisions in the agreements.
The company also reiterated that these expectations are forward-looking and could be affected by factors such as intellectual property challenges, litigation outcomes, regulatory changes, and broader business risks described in its prior annual and quarterly reports.
AbbVie Inc. (ABBV) Form 144 notice: An insider proposes to sell 62,755 shares of common stock through Morgan Stanley Smith Barney LLC on 08/22/2025. The shares were acquired the same day via a stock option exercise and paid for in cash. The filing lists an aggregate market value for the proposed sale of $13,231,264.20 and reports 1,766,558,253 shares outstanding for the class. The filer also reported four prior common-stock sales in August 2025 by Richard A. Gonzalez: 61,500 shares on 08/01/2025 (gross proceeds $12,043,268.25), 35,120 shares and 91,600 shares on 08/04/2025 (gross proceeds $6,828,296.22 and $19,208,000.00 respectively), and 90,000 shares on 08/21/2025 (gross proceeds $18,993,947.76). The filer certifies no undisclosed material adverse information and acknowledges legal penalties for false statements.
AbbVie insider sale notice: This Form 144 shows that Richard A. Gonzalez intends to sell 90,000 AbbVie (ABBV) common shares through Morgan Stanley Smith Barney on 08/21/2025 with an aggregate market value of $18,993,947.76. The filing reports Abbies outstanding shares as 1,766,558,253, so the planned sale represents a small fraction of total shares. The 90,000 shares were acquired the same day, 08/21/2025, by stock option exercise and paid for in cash.
The filing also discloses recent insider sales by Richard A. Gonzalez during the past three months: 61,500 shares sold 08/01/2025 for $12,043,268.25; 35,120 shares sold 08/04/2025 for $6,828,296.22; and 91,600 shares sold 08/04/2025 for $19,208,000. The notice includes the standard insider representation that no undisclosed material adverse information is known.
Azita Saleki-Gerhardt, Executive Vice President and Chief Operations Officer of AbbVie Inc. (ABBV), reported transactions on 08/12/2025 showing she exercised employee stock options and simultaneously sold the resulting shares. She acquired 42,370 shares through exercise at a reported exercise price of $54.86 per share and sold 42,370 shares the same day at a weighted-average sale price of $198.42 per share. Following these transactions, her reported direct beneficial ownership decreased from 219,662 shares to 177,292 shares. The Form 4 notes 2,647 shares are held in an AbbVie savings program and 3,873 shares are held by her spouse (for which she disclaims beneficial ownership). The transactions were reported by an attorney-in-fact and the filing includes an explanatory footnote that the sale prices reported represent a range of prices between $198.34 and $198.58.
AbbVie filed a Form 144 reporting a proposed sale of 42,370 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,407,068.11. The filing lists the approximate date of sale as 08/12/2025 and shows the shares were acquired by a stock option exercise on 08/12/2025 with payment in cash.
The notice states there were no securities sold in the past three months by the person for whose account the shares are to be sold. The filing includes the total number of shares outstanding as 1,766,558,253, and identifies the executing broker and the class of security as common stock. No additional transaction context or identities are provided in the document.